Image source: Adobe Stock/6okean

News • Glycemia assessment

Using machine learning to predict poor glycemic control in patients with type 2 diabetes

The risk for poor glycemic control in patients with type 2 diabetes can be predicted with confidence by using machine learning methods, a new study from Finland finds. The most important factors predicting glycemic control include prior glucose levels, duration of type 2 diabetes, and the patient’s existing anti-diabetic medicines.

The most important factors predicting glycemic control include prior glucose levels, duration of type 2 diabetes, and the patient’s existing anti-diabetic medicines. The research has been published in the Journal Clinical Epidemiology.

The researchers examined glycemic control in patients with type 2 diabetes in North Karelia, Finland, over a period of six years. Patients’ glycemic control was determined on the basis of long-term blood glucose, HbA1c. Three HbA1c trajectories were identified from the data, and based on these, patients were divided into two groups: patients with adequate glycemic control, and patients with inadequate glycemic control. Using machine learning methods, the researchers examined the association of patients’ baseline characteristics, clinical- and treatment-related factors and socio-economic status with glycemic control. The baseline characteristics included more than 200 different variables. 

The results showed that by using data on the duration of type 2 diabetes, prior HbA1c levels, fasting blood glucose, existing anti-diabetic medicines and their number, it is possible to reliably identify patients with a persistent risk for hyperglycemia at any point of their disease. In other words, inadequate glycemic control can be predicted from data that is routinely collected as part of diabetes monitoring and management. The primary objective of treatment in type 2 diabetes is to maintain good glycemic control in order to prevent complications associated with the disease. According to the Finnish Current Care Guidelines for Diabetes, glycemic control should be followed up annually, making it possible to monitor the long-term trajectory of the disease. Early identification of patients with poor glycemic control is of paramount importance in order to target treatment to those in need and to intensify it at the right time. Delayed intensification of treatment increases the risk of complications, which is also reflected in higher costs of care. 

Estimated HbA1c trajectories. Solid line represents average HbA1c and dotted...
Estimated HbA1c trajectories. Solid line represents average HbA1c and dotted lines 95% confidence interval for the mean.

Image source: Lavikainen et al., Clinical Epidemiology 2022 (CC BY-NC 3.0)

The study utilised data from the electronic patient information system of the Joint Municipal Authority for North Karelia Social and Health Services, Siun sote, from registers maintained by the Social Insurance Institution of Finland, as well as from Statistics Finland’s open postal code database, Paavo.  A total of 9,631 people with type 2 diabetes were selected for the study cohorts. The study was carried out in collaboration the University of Eastern Finland and the University of Oulu, and it was funded by the Finnish Diabetes Association, the Strategic Research Council at the Academy of Finland, Kuopio University Hospital (VTR funding) and the HTx project funded by the EU Horizon 2020 programme


Source: University of Eastern Finland 

06.01.2023

Read all latest stories

Related articles

Photo

News • Devil in the details

Why healthcare researchers must be wary of misusing AI

An international team of researchers advises that strong care needs to be taken not to misuse or overuse machine learning (ML) in healthcare research, despite all of its benefits.

Photo

News • Identificación de mutaciones tumorales

El aprendizaje automático impulsa la medicina personalizada del cáncer

El laboratorio de Genómica Biomédica del IRB Barcelona (Institute for Research in Biomedicine) ha desarrollado un método computacional que identifica las mutaciones causantes del cáncer para cada…

Photo

News • Tool to identify tumour mutations

Machine learning fuels personalised cancer medicine

The Biomedical Genomics laboratory at the Institute for Research in Biomedicine (IRB) Barcelona has developed a computational tool that identifies cancer driver mutations for each tumour type. This…

Related products

Agfa HealthCare · Rubee for AI

Artificial Intelligence

Agfa HealthCare · Rubee for AI

Agfa HealthCare
Canon · Advanced intelligent Clear-IQ Engine for MR

Artificial Intelligence

Canon · Advanced intelligent Clear-IQ Engine for MR

Canon Medical Systems Europe B.V.
Canon · Aquilion Exceed LB

Oncology CT

Canon · Aquilion Exceed LB

Canon Medical Systems Europe B.V.
Canon · Aquilion Lightning

20 to 64 Slices

Canon · Aquilion Lightning

Canon Medical Systems Europe B.V.
Canon · Aquilion Lightning SP

Volume CT

Canon · Aquilion Lightning SP

Canon Medical Systems Europe B.V.
Subscribe to Newsletter